 |
 Video: What is a Stock Split?
|
|
|
| Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. Co. is focused on developing the following product candidates: LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies; LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator in preclinical studies for multiple neurological diseases; and LP143, a centrally acting, full cannabinoid type 2 receptor agonist in preclinical studies for central nervous system diseases and disorders. According to our Longboard Pharmaceuticals stock split history records, Longboard Pharmaceuticals has had 0 splits. | |
|
Longboard Pharmaceuticals (LBPH) has 0 splits in our Longboard Pharmaceuticals stock split history database.
Looking at the Longboard Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Longboard Pharmaceuticals shares, starting with a $10,000 purchase of LBPH, presented on a split-history-adjusted basis factoring in the complete Longboard Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/15/2021 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$16.89 |
|
| End price/share: |
$21.38 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
26.55% |
|
| Average Annual Total Return: |
7.80% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$12,656.82 |
|
| Years: |
3.14 |
|
|
|
|
|
